SCHEMBL3314915

SCHEMBL3314915

O=[N+]([O-])c1ccccc1S(=O)(=O)N(Cc1cccc(CNC2CCCCc3cccnc32)c1)Cc1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.42
HDAC1 Q13547 2/20 0.42
CXCR3 P49682 6/20 0.41
CXCR4 P61073 3/20 0.40
CYP19A1 P11511 1/20 0.38
PTPN1 P18031 2/20 0.38
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KCNA5 P22460 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313097 0.98 HDAC6 (0.42) HDAC6HDAC1CXCR3CXCR4CYP19A1
SCHEMBL3314317 0.94 HDAC6 (0.46) HDAC6HDAC1CXCR3CXCR4PTPN1
SCHEMBL3312846 0.92 HDAC6 (0.48) HDAC6HDAC1CXCR3CXCR4PTPN1
SCHEMBL5576505 0.82 PTPN1 (0.38) HDAC6HDAC1CXCR3CXCR4PTPN1
SCHEMBL3314918 0.80 CYP19A1 (0.48) HDAC6CXCR3CYP19A1PTPN1ALDH1A1
SCHEMBL30338365 0.80 HDAC6 (0.51) HDAC6HDAC1CXCR3CXCR4LMNA
SCHEMBL4069997 0.79 PDE4A (0.42) HDAC6CXCR3PTPN1ALDH1A1LMNA
SCHEMBL3314059 0.78 CXCR4 (0.56) CXCR4
SCHEMBL3311009 0.78 KCNA5 (0.40) HDAC6CXCR3PTPN1LMNASMN1; SMN2
SCHEMBL3312434 0.77 CXCR3 (0.46) HDAC6CXCR3CYP19A1PTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2010-04-29 US disclosed
US-7629337-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2009-12-08 US disclosed
US-7183273-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2007-02-27 US disclosed
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds ANORMED INC. (CA) 2006-11-23 US disclosed
EP-1163238-B1 CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2006-05-31 EP disclosed
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-25 US disclosed
US-6750348-B1 PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE ANORMED, INC. (CA) 2004-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264434-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 HDAC6 1137/4885HDAC1 950/4885CXCR3 4/4885
US-20100105915-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CXCR4, CCR5, CXCR3 HDAC6 1168/4885HDAC1 836/4885CXCR3 3/4885
US-20040235823-A1 Chemokine receptor binding heterocyclic compounds CCR5, CXCR4, CXCR1 HDAC6 1089/4885HDAC1 1116/4885CXCR3 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.